Journey Medical Corp (DERM) Stock Price, Quote & News

Company Profile

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 480 434 6670

Website: journeymedicalcorp.com

Address:

9237 East Via de Ventura Blvd., Suite 105, Scottsdale, United States

liamsniperalert Jul. 15 at 2:45 PM

$DERM 10 CALL 8/21 @ .30 🗻

0 · Reply

LUXtrades0 Jul. 15 at 2:44 PM

$DERM 10 Call 8/21 here

0 · Reply

LUXtrades0 Jul. 15 at 2:43 PM

$DERM 10 Call 8/21 at 0.30

0 · Reply

Tomasini Jul. 15 at 2:27 PM

$DERM pretty big moves last two days on low volume. news leak?

0 · Reply

Tomasini Jul. 14 at 2:24 PM

$DERM $32 million emrosi per year should put $20 million to bottom line or .80$/share. assuming everything else is breakeven and p/e of 15 gets us to $12 by end of year. very doable

0 · Reply

buymoremakemore Jul. 13 at 7:13 PM

$DERM Time for shorts to cover. 23% gain in Emrosi prescriptions from Q1 to Q2 means more revenue, especially since more time has passed in insurance reimbursement talks with PBMs and DERM contracting with the 3rd GPO in the middle of Q2.

0 · Reply

buymoremakemore Jul. 13 at 5:43 PM

$DERM shoutout to rainbowroll2016 on X for giving me the rx count for Q2 from Bloomberg. 36.9k nearly 37k!! 7000/23% more than Q1. Insane. If price per prescription stays same from Q1 it is a 1.5M increase in revenue for Q2. I think 8.5M Emrosi revenue could be on deck for Q2. Things looking good

1 · Reply

buymoremakemore Jul. 11 at 5:49 PM

$DERM Looks like the Lupin Emrosi patent lawsuit was reassigned to another judge. Lupin are such parasites. They have an aggressive patent challenge strategy. I still believe they don't have a good case and theyre just doing this because DERM's cash position is low. Just a hail mary over next 2 years if anything happens to Journey. Lupin has a history of losing patent challenege lawsuits and paying million dollar settlements. Galaderma defended Oracea's IP for many years from several generic manufacturers until several key patents expired. So, Im not really worried. It was expected people would challenge patents.

1 · Reply

CH_Expat Jul. 8 at 6:33 PM

$DERM , $DBVT and $NRIX are the only serious candidates to bring some of my $CRNX profits to right now, but not for the current valuations. None of the names really thrill me. If the imevitable mega correction comes, I might also average up IDYA and MLYS

2 · Reply

omega42 Jul. 8 at 4:20 PM

$DERM few things to keep in mind; Q1 was impacted by multiple winter storms which held back some of the revenue; q2&q3 are high season for rosacea which means that scripts should be very strong in both with 33-36k scripts expected in q2. THe only unknow is ASP and if they can elevate that from Q1 it should be a very upbeat ER next month

0 · Reply

Journey Medical Transcript: AGM 2026

May 20, 2026, 5:00 PM EDT - 2 months ago

Journey Medical Transcript: A.G.P.'s Annual Virtual Healthcare Conference

May 19, 2026, 4:45 PM EDT - 2 months ago

Market Cap	196.05M
Revenue (ttm)	61.86M
Net Income (ttm)	-11.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	39.20
Profit Margin	-18.48%
Debt to Equity Ratio	0.82

Volume	149,100
Avg Vol	294,526
Day's Range	N/A - N/A
Shares Out	27.54M
Stochastic %K	80%
Beta	1.07
Analysts	Strong Sell
Price Target	$13.50